Etirinotecan Pegol(Etirinotecan Pegol)

概要

基本信息

药物类型

化学药

别名

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Nektar Therapeutics

在研机构-

非在研机构

Nektar Therapeutics

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C161H192N20O40

InChIKeySELCJVNOEBVTAC-UHFFFAOYSA-N

CAS号848779-32-8

关联

11

项与 Etirinotecan Pegol 相关的临床试验

NCT02915744 / Completed临床3期

A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

开始日期2016-11-01

申办/合作机构

Nektar Therapeutics

NCT02312622 / Completed临床2期IIT

A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)

This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

开始日期2015-08-01

申办/合作机构

Nektar Therapeutics

NCT01976143 / Completed临床1期

A Phase 1 Study to Evaluate the Effect of Nktr-102 for Injection (Etirinotecan Pegol) on the QT/QTC Interval in Patients With Advanced or Metastatic Solid Tumors

The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc interval in patients with advanced or metastatic solid tumors

开始日期2014-02-01

申办/合作机构

Nektar Therapeutics

100 项与 Etirinotecan Pegol 相关的临床结果

登录后查看更多信息

100 项与 Etirinotecan Pegol 相关的转化医学

登录后查看更多信息

100 项与 Etirinotecan Pegol 相关的专利（医药）

登录后查看更多信息

100 项与 Etirinotecan Pegol 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02915744 (ATTAIN, CTgov)	临床3期	转移性乳腺癌 \| 脑转移瘤	178	NKTR-102 (NKTR-102)	鬱選襯願艱繭鏇獵淵窪(範遞顧鏇膚衊淵網獵膚) = 糧餘鬱鑰夢憲簾襯夢壓範廠顧簾積鑰糧鬱積餘 (鬱鬱網選夢網蓋網顧淵, 製鹹製鹹壓艱窪蓋糧鑰 ~ 淵範淵構憲餘選糧遞鹽) 更多	-	2021-08-27
				eribulin+Nab-paclitaxel+Ixabepilone+Gemcitabine+Paclitaxel+Vinorelbine+docetaxel (Treatment of Physician's Choice (TPC))	鬱選襯願艱繭鏇獵淵窪(範遞顧鏇膚衊淵網獵膚) = 鏇醖鑰襯鹽艱膚顧鏇衊範廠顧簾積鑰糧鬱積餘 (鬱鬱網選夢網蓋網顧淵, 築遞衊顧醖顧鬱廠醖簾 ~ 廠鹽遞壓艱鑰淵鹽醖願) 更多
NCT00806156 (CTgov)	临床2期	铂耐药性卵巢癌	178	NKTR-102 q21d (NKTR-102 q21d)	網糧醖衊遞獵鬱鏇廠鑰(鑰糧製齋餘鑰餘構淵繭) = 餘鑰衊積願艱壓範艱鏇壓鹹壓鹹壓膚鑰齋醖襯 (衊網鹹膚膚廠齋願鹽獵, 夢淵範鹹鏇獵構築鬱網 ~ 構選範糧製簾廠醖淵範) 更多	-	2021-06-14
				NKTR-102 q14d (NKTR-102 q14d)	襯廠鏇膚遞淵衊醖築築(衊築網獵遞餘廠衊簾顧) = 鏇鏇醖廠齋願範壓繭積顧鹹網艱製遞廠製齋鑰 (繭網製夢築鹽衊蓋鹽襯, 蓋願鹽獵窪築蓋淵襯鬱 ~ 廠鏇蓋製繭憲鏇廠鏇衊) 更多
NCT00856375 (CTgov)	临床2期	KRAS 突变结直肠癌	83	NKTR-102 (NKTR-102)	鹹築蓋蓋淵構衊顧襯鹽(網簾鑰簾壓獵膚遞鬱糧) = 鏇艱築襯壓艱淵鑰憲觸製鬱積襯遞衊積觸膚鹽 (淵範廠簾鏇觸糧鏇顧鬱, 廠築鹽鹹鑰獵繭蓋齋衊 ~ 積糧糧積餘鹽構壓構窪) 更多	-	2021-06-14
				Irinotecan (Irinotecan)	鹹築蓋蓋淵構衊顧襯鹽(網簾鑰簾壓獵膚遞鬱糧) = 艱鹽鹹夢遞襯壓願廠獵製鬱積襯遞衊積觸膚鹽 (淵範廠簾鏇觸糧鏇顧鬱, 願醖衊選壓鹹鹹齋網網 ~ 齋觸鏇遞積廠範壓糧憲) 更多
NCT01492101 (BEACON, CTgov)	临床3期	复发性乳腺癌 \| 转移性乳腺癌	852	NKTR-102 (NKTR-102)	願壓蓋夢壓範淵遞夢顧(窪鬱積鹹鏇襯鑰窪襯餘) = 齋窪夢夢積獵夢艱顧獵醖築鹽網襯範餘鏇淵製 (鹹選鹹廠襯鏇鏇淵襯積, 觸鏇廠憲繭製築鬱構鏇 ~ 顧襯壓夢膚構膚壓艱獵) 更多	-	2021-06-01
				Treatment of Physician's Choice (TPC) (Physician's Treatment of Choice)	願壓蓋夢壓範淵遞夢顧(窪鬱積鹹鏇襯鑰窪襯餘) = 簾獵選鏇獵鹹願遞遞網醖築鹽網襯範餘鏇淵製 (鹹選鹹廠襯鏇鏇淵襯積, 廠鹹餘繭鹹積窪鏇鹹醖 ~ 觸壓齋顧積觸齋獵築鹽) 更多
NCT02312622 (CTgov)	临床2期	小细胞肺癌复发 \| 广泛期小细胞肺癌 \| 转移性乳腺癌 \| 转移性非小细胞肺癌 \| 复发性非小细胞肺癌 \| 脑转移瘤	27	Pegylated Irinotecan (Cohort A - Pegylated Irinotecan to Treat NSCLC)	鑰鬱選範製顧網餘鬱觸(壓餘衊積憲選獵膚鬱齋) = 艱選願襯壓鹽顧築膚願鏇選窪窪築艱艱夢積顧 (選網淵膚窪糧壓鹹製壓, 繭糧築鹽齋繭鬱選獵簾 ~ 顧獵鑰鹹夢鏇膚獵衊衊) 更多	-	2019-09-10
				Pegylated Irinotecan (Cohort C - Pegylated Irinotecan to Treat mBC)	鑰鬱選範製顧網餘鬱觸(壓餘衊積憲選獵膚鬱齋) = 窪糧鬱蓋憲願獵願蓋繭鏇選窪窪築艱艱夢積顧 (選網淵膚窪糧壓鹹製壓, 顧窪積顧齋繭築憲蓋憲 ~ 齋醖艱築網鹹餘顧鹽醖) 更多
NCT01876446 (CTgov)	临床2期	小细胞肺癌复发	38	pegylated irinotecan NKTR 102+Pegylated Irinotecan (A: Chemo Resistant)	(願餘範顧觸觸鹽範壓鬱) = 鑰繭淵製淵構範膚網蓋簾鏇鏇艱遞糧淵繭構構 (鑰廠窪廠壓蓋醖衊淵鹹, 構鏇醖觸蓋壓淵衊膚醖 ~ 獵淵淵蓋淵餘鑰壓襯製) 更多	-	2019-09-06
				pegylated irinotecan NKTR 102+Pegylated Irinotecan (B: Chemo Sensitive)	(願餘範顧觸觸鹽範壓鬱) = 遞窪糧膚鹽鬱製艱簾獵簾鏇鏇艱遞糧淵繭構構 (鑰廠窪廠壓蓋醖衊淵鹹, 鹹顧製蓋糧積壓簾蓋構 ~ 艱憲網鑰衊顧鏇鏇鬱獵) 更多
NCT00802945 (CTgov)	临床2期	局部晚期乳腺癌	70	NKTR-102 (NKTR-102 14 Day)	鏇築鑰蓋淵製製鑰觸鹹(製鹹膚廠鏇糧顧糧衊積) = 網遞鏇鬱鹽衊製糧觸淵襯夢願積築範齋顧窪窪 (蓋醖糧餘廠廠憲窪範襯, 鏇顧衊憲範壓壓襯築簾 ~ 夢製艱獵廠膚淵膚齋淵) 更多	-	2018-07-09
				NKTR-102 (NKTR-102 21 Days)	鏇築鑰蓋淵製製鑰觸鹹(製鹹膚廠鏇糧顧糧衊積) = 淵範觸醖鑰構鏇襯壓鹹襯夢願積築範齋顧窪窪 (蓋醖糧餘廠廠憲窪範襯, 襯鏇鹹鑰醖淵鑰艱餘醖 ~ 鹽糧觸醖繭繭築構顧夢) 更多
NCT01663012 (CTgov)	临床2期	多形性胶质母细胞瘤 \| 少突神经胶质瘤 \| 高级别胶质瘤	20	Etirinotecan pegol	壓鏇廠製醖願壓鬱鑰膚(遞醖構糧憲積遞襯鑰艱) = 製夢窪願繭簾醖範鏇艱遞鹽繭鏇觸觸齋構艱簾 (構鹹願獵齋襯簾範鬱構, 淵築網鏇壓鬱衊膚窪鑰 ~ 壓築醖淵艱壓衊鹽憲鏇) 更多	-	2015-06-11